Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Immuneering (IMRX) Return on Capital Employed (2021 - 2026)

Immuneering's Return on Capital Employed history spans 6 years, with the latest figure at 27.12% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 11075.0% to 27.12% in Q1 2026 year-over-year; TTM through Mar 2026 was 27.12%, a 11075.0% increase, with the full-year FY2025 number at 44.89%, up 4645.0% from a year prior.
  • Return on Capital Employed came in at 27.12% for Q1 2026, down from 26.22% in the prior quarter.
  • The five-year high for Return on Capital Employed was 26.03% in Q1 2022, with the low at 169.14% in Q2 2025.
  • Historically, Return on Capital Employed has averaged 65.46% across 5 years, with a median of 49.31% in 2023.
  • Biggest five-year swings in Return on Capital Employed: crashed -8932bps in 2025 and later surged 11075bps in 2026.
  • Year by year, Return on Capital Employed stood at 43.13% in 2022, then crashed by -35bps to 58.19% in 2023, then tumbled by -107bps to 120.59% in 2024, then surged by 78bps to 26.22% in 2025, then decreased by -3bps to 27.12% in 2026.
  • Business Quant data shows Return on Capital Employed for IMRX at 27.12% in Q1 2026, 26.22% in Q4 2025, and 48.99% in Q3 2025.